ImmunityBio's research reveals that its bladder cancer treatment works well over a long time.

IBRX · ImmunityBio, Inc.

The AI's read

Long-lasting responses and survival data add support for a treatment already cleared for use. The study does not show how many patients will use ANKTIVA or how much sales may grow. The article also notes weaker short-term trading signals, but those do not undo the clinical evidence.